FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3025165054> ?p ?o ?g. }

• W3025165054 endingPage "531" @default.
• W3025165054 startingPage "528" @default.
• W3025165054 abstract "Objective: To evaluate the incidence of invasive fungal infections (IFI) and usage of intravenous antifungal drugs during remission induction chemotherapy in patients with acute myeloid leukemia (AML) under primary antifungal prophylaxis with posaconazole. Methods: Clinical records from newly diagnosed AML patients above 15 years old in one single center from February 2014 to January 2016 were retrospectively reviewed and analyzed, excluding acute promyelocytic leukemia. The incidence of IFI and usage of intravenous antifungal drugs were investigated between control group (not receiving any broad spectrum antifungal prophylaxis) and treatment group (receiving posaconazole as primary prophylaxis). Results: A total of 147 newly diagnosed AML patients were enrolled. Of them, 81 received prophylaxis with posaconazole, and 66 did not receive broad-spectrum antifungal treatment. 7 IFI occurred in posaconazole group, and all were possible cases; 19 IFI occurred in control group (3 proven, 4 probable, 12 possible). The incidence of IFI was significantly lower in treatment group than that in control group (8.6% vs 28.8%, χ(2)=10.138, P=0.001). Usage of intravenous antifungal drugs was significantly decreased in posaconazole group (18.5% vs 50.0%, χ(2)=16.390, P<0.001). Conclusion: Prophylaxis with posaconazole coulf prevent IFI and reduce usage of intravenous antifungal drugs significantly during remission induction chemotherapy in AML patients.目的： 研究泊沙康唑初级预防急性髓系白血病（AML）诱导化疗期侵袭性真菌感染（IFI）的发生率及静脉抗真菌药物使用率。 方法： 回顾性分析2014年2月至2016年1月≥15岁初诊且接受初始缓解诱导化疗的147例AML（除外急性早幼粒细胞白血病）患者，观察诱导化疗期间接受泊沙康唑抗真菌预防治疗（泊沙康唑组）和未进行广谱抗真菌预防治疗（对照组）IFI的发生率及静脉抗真菌药物使用率。 结果： 147例患者中，81例诱导化疗期间接受泊沙康唑抗真菌预防治疗，为泊沙康唑组；66例未进行广谱抗真菌预防，为对照组。泊沙康唑组中7例发生IFI，发生率为8.6%，均为拟诊病例。对照组患者中19例发生IFI，发生率为28.8%，其中确诊3例，临床诊断4例，拟诊12例。泊沙康唑组IFI发生率显著低于对照组（χ(2)=10.138，P=0.001）。泊沙康唑组静脉抗真菌药物使用率为18.5%（15/81），显著低于对照组的50.0%（33/66）（χ(2)=16.390，P<0.001）。 结论： 应用泊沙康唑在AML诱导化疗期间进行IFI初级预防，能够显著降低IFI发生率及静脉抗真菌药物使用率。." @default.
• W3025165054 created "2020-05-21" @default.
• W3025165054 creator A5000937050 @default.
• W3025165054 creator A5005382729 @default.
• W3025165054 creator A5009909096 @default.
• W3025165054 creator A5013800022 @default.
• W3025165054 creator A5016508145 @default.
• W3025165054 creator A5023897428 @default.
• W3025165054 creator A5045492537 @default.
• W3025165054 creator A5048444713 @default.
• W3025165054 creator A5051337665 @default.
• W3025165054 creator A5057082991 @default.
• W3025165054 creator A5058986577 @default.
• W3025165054 creator A5067006313 @default.
• W3025165054 creator A5075101614 @default.
• W3025165054 creator A5081348340 @default.
• W3025165054 creator A5084070779 @default.
• W3025165054 creator A5086609279 @default.
• W3025165054 creator A5089264056 @default.
• W3025165054 date "2017-06-14" @default.
• W3025165054 modified "2023-10-15" @default.
• W3025165054 title "[Primary antifungal prophylaxis with posaconazole plays a pivotal role during chemotherapy of acute myeloid leukemia]." @default.
• W3025165054 cites W1954565136 @default.
• W3025165054 cites W1984427908 @default.
• W3025165054 cites W1989345554 @default.
• W3025165054 cites W2009143281 @default.
• W3025165054 cites W2051707222 @default.
• W3025165054 cites W2056158943 @default.
• W3025165054 cites W2107040094 @default.
• W3025165054 cites W2165549415 @default.
• W3025165054 cites W2170531065 @default.
• W3025165054 cites W2329302065 @default.
• W3025165054 cites W772755644 @default.
• W3025165054 doi "https://doi.org/10.3760/cma.j.issn.0253-2727.2017.06.012" @default.
• W3025165054 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7342978" @default.
• W3025165054 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28655098" @default.
• W3025165054 hasPublicationYear "2017" @default.
• W3025165054 type Work @default.
• W3025165054 sameAs 3025165054 @default.
• W3025165054 citedByCount "1" @default.
• W3025165054 countsByYear W30251650542018 @default.
• W3025165054 crossrefType "journal-article" @default.
• W3025165054 hasAuthorship W3025165054A5000937050 @default.
• W3025165054 hasAuthorship W3025165054A5005382729 @default.
• W3025165054 hasAuthorship W3025165054A5009909096 @default.
• W3025165054 hasAuthorship W3025165054A5013800022 @default.
• W3025165054 hasAuthorship W3025165054A5016508145 @default.
• W3025165054 hasAuthorship W3025165054A5023897428 @default.
• W3025165054 hasAuthorship W3025165054A5045492537 @default.
• W3025165054 hasAuthorship W3025165054A5048444713 @default.
• W3025165054 hasAuthorship W3025165054A5051337665 @default.
• W3025165054 hasAuthorship W3025165054A5057082991 @default.
• W3025165054 hasAuthorship W3025165054A5058986577 @default.
• W3025165054 hasAuthorship W3025165054A5067006313 @default.
• W3025165054 hasAuthorship W3025165054A5075101614 @default.
• W3025165054 hasAuthorship W3025165054A5081348340 @default.
• W3025165054 hasAuthorship W3025165054A5084070779 @default.
• W3025165054 hasAuthorship W3025165054A5086609279 @default.
• W3025165054 hasAuthorship W3025165054A5089264056 @default.
• W3025165054 hasConcept C104317684 @default.
• W3025165054 hasConcept C120665830 @default.
• W3025165054 hasConcept C121332964 @default.
• W3025165054 hasConcept C126322002 @default.
• W3025165054 hasConcept C16005928 @default.
• W3025165054 hasConcept C2776601000 @default.
• W3025165054 hasConcept C2776694085 @default.
• W3025165054 hasConcept C2778566413 @default.
• W3025165054 hasConcept C2778729363 @default.
• W3025165054 hasConcept C2779548794 @default.
• W3025165054 hasConcept C2780690907 @default.
• W3025165054 hasConcept C2781121885 @default.
• W3025165054 hasConcept C55493867 @default.
• W3025165054 hasConcept C61511704 @default.
• W3025165054 hasConcept C71924100 @default.
• W3025165054 hasConcept C86803240 @default.
• W3025165054 hasConcept C90924648 @default.
• W3025165054 hasConceptScore W3025165054C104317684 @default.
• W3025165054 hasConceptScore W3025165054C120665830 @default.
• W3025165054 hasConceptScore W3025165054C121332964 @default.
• W3025165054 hasConceptScore W3025165054C126322002 @default.
• W3025165054 hasConceptScore W3025165054C16005928 @default.
• W3025165054 hasConceptScore W3025165054C2776601000 @default.
• W3025165054 hasConceptScore W3025165054C2776694085 @default.
• W3025165054 hasConceptScore W3025165054C2778566413 @default.
• W3025165054 hasConceptScore W3025165054C2778729363 @default.
• W3025165054 hasConceptScore W3025165054C2779548794 @default.
• W3025165054 hasConceptScore W3025165054C2780690907 @default.
• W3025165054 hasConceptScore W3025165054C2781121885 @default.
• W3025165054 hasConceptScore W3025165054C55493867 @default.
• W3025165054 hasConceptScore W3025165054C61511704 @default.
• W3025165054 hasConceptScore W3025165054C71924100 @default.
• W3025165054 hasConceptScore W3025165054C86803240 @default.
• W3025165054 hasConceptScore W3025165054C90924648 @default.
• W3025165054 hasIssue "6" @default.
• W3025165054 hasLocation W30251650541 @default.
• W3025165054 hasOpenAccess W3025165054 @default.
• W3025165054 hasPrimaryLocation W30251650541 @default.
• W3025165054 hasRelatedWork W2003938723 @default.

• next